Home
CNTA
CNTA News

Latest Centessa Pharmaceuticals plc (CNTA) News on May 10, 2025

MT Newswires

2 days ago

Chardan Initiates Centessa Pharmaceuticals at Buy With $30 Price Target

Is Centessa Pharmaceuticals plc (CNTA) the Best Small Cap Stock to Buy with the Biggest Upside Potential?

Insider Monkey

5 days ago

Is Centessa Pharmaceuticals plc (CNTA) the Best Small Cap Stock to Buy with the Biggest Upside Potential?

MT Newswires

17 days ago

Centessa Pharmaceuticals Insider Sold Shares Worth $681,576, According to a Recent SEC Filing

MT Newswires

a month ago

Piper Sandler Initiates Centessa Pharmaceuticals at Overweight With $38 Price Target

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

GlobeNewswire

2 months ago

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

GlobeNewswire

2 months ago

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

MT Newswires

3 months ago

Centessa Pharmaceuticals Insider Sold Shares Worth $588,944, According to a Recent SEC Filing

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

3 months ago

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Why Is Centessa Pharmaceuticals (CNTA) Among the Best Medical Stocks to Buy Under $20?

Insider Monkey

4 months ago

Why Is Centessa Pharmaceuticals (CNTA) Among the Best Medical Stocks to Buy Under $20?

Is Centessa Pharmaceuticals plc (CNTA) the Best Growth Stock to Buy Now Under $25?

Insider Monkey

4 months ago

Is Centessa Pharmaceuticals plc (CNTA) the Best Growth Stock to Buy Now Under $25?

Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

GlobeNewswire

4 months ago

Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

MT Newswires

4 months ago

TD Cowen Initiates Centessa Pharmaceuticals ADR at Buy

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Could Be 30% Below Their Intrinsic Value Estimate

Simply Wall St.

4 months ago

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Could Be 30% Below Their Intrinsic Value Estimate

MT Newswires

4 months ago

Centessa Pharmaceuticals Secures Loan Facility, Repays Debt

MT Newswires

5 months ago

Centessa Pharmaceuticals Insider Sold Shares Worth $959,057, According to a Recent SEC Filing

Why Did Centessa Pharmaceuticals PLC (CNTA) Jump Yesterday?

Insider Monkey

5 months ago

Why Did Centessa Pharmaceuticals PLC (CNTA) Jump Yesterday?

MT Newswires

5 months ago

Centessa Pharmaceuticals Insider Sold Shares Worth $284,010, According to a Recent SEC Filing

MT Newswires

5 months ago

Centessa Pharmaceuticals Insider Sold Shares Worth $1,615,255, According to a Recent SEC Filing

MT Newswires

6 months ago

Morgan Stanley Lifts Price Target on Centessa Pharmaceuticals to $27 From $26, Keeps Overweight Rating

Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing

BioPharma Dive

6 months ago

Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing

MT Newswires

6 months ago

Centessa Pharmaceuticals' Q3 Loss Widens

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

GlobeNewswire

6 months ago

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

6 months ago

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

MT Newswires

7 months ago

Centessa Pharmaceuticals Insider Sold Shares Worth $863,727, According to a Recent SEC Filing

Centessa Pharmaceuticals Plc (CNTA): A Small-Cap Leader in Clinical-Stage Biotech

Insider Monkey

7 months ago

Centessa Pharmaceuticals Plc (CNTA): A Small-Cap Leader in Clinical-Stage Biotech

Analysts Rate Centessa Pharmaceuticals Plc (CNTA) as Strong Buy Amid Promising Developments

Insider Monkey

7 months ago

Analysts Rate Centessa Pharmaceuticals Plc (CNTA) as Strong Buy Amid Promising Developments

Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

GlobeNewswire

7 months ago

Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

MT Newswires

8 months ago

Centessa Pharmaceuticals Shares Rise After Upgrade From Morgan Stanley

MT Newswires

8 months ago

Morgan Stanley Upgrades Centessa Pharmaceuticals to Overweight From Equalweight, Adjusts PT to $26 From $11

MT Newswires

8 months ago

Update: B. Riley Initiates Centessa Pharmaceuticals at Buy With $33 Price Target

MT Newswires

8 months ago

B. Riley Initiates Centessa Pharmaceuticals at Buy

MT Newswires

8 months ago

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday

MT Newswires

8 months ago

Sector Update: Health Care

MT Newswires

8 months ago

Centessa Pharmaceuticals Prices Upsized $225 Million Public Offering

MT Newswires

8 months ago

Centessa Pharmaceuticals Insider Sold Shares Worth $2,891,823, According to a Recent SEC Filing

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

GlobeNewswire

8 months ago

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

MT Newswires

8 months ago

Centessa Pharmaceuticals Files Mixed Shelf; Launches $150 Million Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

GlobeNewswire

8 months ago

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Reverses Lower Despite $5 Billion Narcolepsy Opportunity

Investor's Business Daily

8 months ago

Centessa Reverses Lower Despite $5 Billion Narcolepsy Opportunity

MT Newswires

8 months ago

Top Midday Gainers

MT Newswires

8 months ago

Sector Update: Health Care Stocks Rise in Afternoon Trading

MT Newswires

8 months ago

Sector Update: Health Care

MT Newswires

8 months ago

Centessa Pharmaceuticals Shares Up After Drug Trial Found to Restore Wakefulness in Subjects

Sleep-Disorder Focused Centessa Pharmaceuticals Unveils Interim Data From Lead Program In Acutely Sleep-Deprived Healthy Volunteers

Benzinga

8 months ago

Sleep-Disorder Focused Centessa Pharmaceuticals Unveils Interim Data From Lead Program In Acutely Sleep-Deprived Healthy Volunteers

Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity

Investor's Business Daily

8 months ago

Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity

Investors are waking up to Centessa’s sleepiness drug

BioPharma Dive

8 months ago

Investors are waking up to Centessa’s sleepiness drug

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

GlobeNewswire

8 months ago

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

MT Newswires

8 months ago

Centessa Pharmaceuticals Insider Sold Shares Worth $375,000, According to a Recent SEC Filing

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

GlobeNewswire

8 months ago

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Insider Sale: Chief Business Officer Gregory Weinhoff Sells 30,000 Shares of Centessa ...

GuruFocus.com

9 months ago

Insider Sale: Chief Business Officer Gregory Weinhoff Sells 30,000 Shares of Centessa ...

MT Newswires

9 months ago

Centessa Pharmaceuticals Insider Sold Shares Worth $573,905, According to a Recent SEC Filing

Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

GlobeNewswire

9 months ago

Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Centessa Pharmaceuticals plc's (NASDAQ:CNTA) high institutional ownership speaks for itself as stock continues to impress, up 18% over last week

Simply Wall St.

9 months ago

Centessa Pharmaceuticals plc's (NASDAQ:CNTA) high institutional ownership speaks for itself as stock continues to impress, up 18% over last week

MT Newswires

9 months ago

Centessa Pharmaceuticals' Q2 Net Loss Widens

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

GlobeNewswire

9 months ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Are Medical Stocks Lagging Stryker (SYK) This Year?

Zacks

9 months ago

Are Medical Stocks Lagging Stryker (SYK) This Year?

MT Newswires

10 months ago

Oppenheimer Initiates Centessa Pharmaceuticals at Outperform Rating With $14 Price Target

Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to Trade

Zacks

10 months ago

Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to Trade

MT Newswires

a year ago

Morgan Stanley Adjusts Price Target on Centessa Pharmaceuticals to $11 From $8, Maintains Equalweight Rating

MT Newswires

a year ago

Centessa Pharmaceuticals Appoints John Crowley as CFO

Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

GlobeNewswire

a year ago

Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

3 Major Product Releases at 3Shape Discover Event

PR Newswire

a year ago

3 Major Product Releases at 3Shape Discover Event

Flash News: OKX Launches 'Trade and Earn' Campaign Featuring 2,500,000 Ultiverse Tokens

GlobeNewswire

a year ago

Flash News: OKX Launches 'Trade and Earn' Campaign Featuring 2,500,000 Ultiverse Tokens

Sustainable Construction Practices and Modular Techniques Drive Dry Construction Market to $127.69 Billion by 2029

GlobeNewswire

a year ago

Sustainable Construction Practices and Modular Techniques Drive Dry Construction Market to $127.69 Billion by 2029

EXCLUSIVE: Sunlight Creates Love Note Projections In New Fred Jewelry Collection

WWD

a year ago

EXCLUSIVE: Sunlight Creates Love Note Projections In New Fred Jewelry Collection

Advantech Releases FWA-3051, The Latest 1U Rackmount Edge Networking Solution with Intel® Xeon® D-2700/2800 Series

PR Newswire

a year ago

Advantech Releases FWA-3051, The Latest 1U Rackmount Edge Networking Solution with Intel® Xeon® D-2700/2800 Series

Hydrogen Storage Market Set to Hit $6.8 Billion by 2031, registering a solid CAGR of 23% - Exclusive Report by Coherent Market Insights

GlobeNewswire

a year ago

Hydrogen Storage Market Set to Hit $6.8 Billion by 2031, registering a solid CAGR of 23% - Exclusive Report by Coherent Market Insights

Shake Shack (SHAK) Rose after Strong Q4 Results

Insider Monkey

a year ago

Shake Shack (SHAK) Rose after Strong Q4 Results

Flash News: OKX to List Ultiverse's Token on its Perpetual Futures Market, Expanding Trading Options

GlobeNewswire

a year ago

Flash News: OKX to List Ultiverse's Token on its Perpetual Futures Market, Expanding Trading Options

Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA)

Zacks

a year ago

Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA)

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

GlobeNewswire

a year ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

MT Newswires

a year ago

Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

GlobeNewswire

a year ago

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

MT Newswires

a year ago

Centessa Pharmaceuticals Eyes $100 Million in ADS Offering

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

GlobeNewswire

a year ago

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

GlobeNewswire

a year ago

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

GuruFocus.com

a year ago

Centessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 Results

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

GlobeNewswire

a year ago

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

Centessa Pharmaceuticals PLC Chief People Officer Sells Company Shares

GuruFocus.com

a year ago

Centessa Pharmaceuticals PLC Chief People Officer Sells Company Shares

Private equity firms who have a significant stake must be disappointed along with institutions after Centessa Pharmaceuticals plc's (NASDAQ:CNTA) market cap dropped by US$139m

Simply Wall St.

a year ago

Private equity firms who have a significant stake must be disappointed along with institutions after Centessa Pharmaceuticals plc's (NASDAQ:CNTA) market cap dropped by US$139m

Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference

GlobeNewswire

a year ago

Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

GlobeNewswire

a year ago

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

Earnings Beat: Harmonic Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Simply Wall St.

a year ago

Earnings Beat: Harmonic Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Kevin Guest Calls on All to Connect during February Month of Friendship

CNW Group

a year ago

Kevin Guest Calls on All to Connect during February Month of Friendship

Thomson Reuters StreetEvents

a year ago

Q4 2023 Two Harbors Investment Corp Earnings Call

4 Accident & Health Insurers to Watch as Underwriting Exposure Increases

Zacks

a year ago

4 Accident & Health Insurers to Watch as Underwriting Exposure Increases

Two Harbors Investment Corp (TWO) Reports Mixed Q4 Results Amid Market Volatility

GuruFocus.com

a year ago

Two Harbors Investment Corp (TWO) Reports Mixed Q4 Results Amid Market Volatility

Two Harbors Investment Corp. Reports Fourth Quarter 2023 Financial Results

Business Wire

a year ago

Two Harbors Investment Corp. Reports Fourth Quarter 2023 Financial Results

Here's Why Momentum in Soleno Therapeutics, Inc. (SLNO) Should Keep going

Zacks

a year ago

Here's Why Momentum in Soleno Therapeutics, Inc. (SLNO) Should Keep going

Bread Financial Holdings (BFH) Tops Q4 Earnings and Revenue Estimates

Zacks

a year ago

Bread Financial Holdings (BFH) Tops Q4 Earnings and Revenue Estimates

Two Harbors Investment Corp. Announces 2023 Dividend Tax Information

Business Wire

a year ago

Two Harbors Investment Corp. Announces 2023 Dividend Tax Information

Fortune Brands Innovations (FBIN) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

a year ago

Fortune Brands Innovations (FBIN) Expected to Beat Earnings Estimates: Should You Buy?

4 Stocks With a Solid Net Profit Margin Worth Buying

Zacks

a year ago

4 Stocks With a Solid Net Profit Margin Worth Buying

monday.com to Announce Fourth Quarter and Fiscal Year 2023 Financial Results on Monday, February 12, 2024

Business Wire

a year ago

monday.com to Announce Fourth Quarter and Fiscal Year 2023 Financial Results on Monday, February 12, 2024

Q3 Earnings Highs And Lows: Inter Parfums (NASDAQ:IPAR) Vs The Rest Of The Personal Care Stocks

StockStory

a year ago

Q3 Earnings Highs And Lows: Inter Parfums (NASDAQ:IPAR) Vs The Rest Of The Personal Care Stocks

Northwest Bancshares (NWBI) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

a year ago

Northwest Bancshares (NWBI) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Is Now An Opportune Moment To Examine Dycom Industries, Inc. (NYSE:DY)?

Simply Wall St.

a year ago

Is Now An Opportune Moment To Examine Dycom Industries, Inc. (NYSE:DY)?

Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances

InvestorPlace

a year ago

Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances

Share on Social Networks: